Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial Group

Research analysts at Jefferies Financial Group started coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a note issued to investors on Monday, Benzinga reports. The firm set a “buy” rating and a $165.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 29.84% from the stock’s current price.

Other analysts have also recently issued reports about the company. Barclays cut their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Raymond James reaffirmed an “outperform” rating and set a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Leerink Partners lifted their price objective on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. Cantor Fitzgerald reissued a “neutral” rating and issued a $152.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, September 20th. Finally, UBS Group raised their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Trading Up 2.3 %

NASDAQ SRPT opened at $127.08 on Monday. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $173.25. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. The stock has a 50 day moving average of $129.00 and a 200-day moving average of $132.36. The company has a market cap of $12.01 billion, a PE ratio of 1,155.27 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics will post 1.45 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Mather Group LLC. bought a new stake in Sarepta Therapeutics during the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics during the second quarter worth about $31,000. New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics in the first quarter valued at approximately $32,000. Finally, GAMMA Investing LLC raised its holdings in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.